DELTA TOCOTRIENOL POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALFA 2-B ON PROLIFERATION, MIGRATION AND INVASION IN HUMAN EA.HY926 UMBILICAL VEIN CELLS

LUCCI, ALVARO; CAPOCASA, JULIETA; VERA, MARINA C; COMANZO, CARLA G; PALMA NICOLÁS; FERRETTI, ANABELLA, C; CEBALLOS MANCINI, MARÍA PAULA; QUIROGA, ARIEL DARÍO; ALVAREZ, MARÍA DEL L.; CARRILLO, MARÍA CRISTINA

Buenos Aires

Congreso; LXVI REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC); 2021

Sociedad Argentina de Investigación Clínica

Our group has postulated supplementation with δ-tocotrienol (E) tointerferon alpha (IFN) therapy as a strategy to treat liver cancer becausethe combined treatment inhibits cell growth and metastaticproperties and increases apoptosis in hepatocarcinoma cells.In this work we studied the effects of the combination of IFN andE on normal angiogenesis, using EA.hy926 human umbilical veinendothelial cells.Our hypothesis is that E supplementation to IFN therapy has significantadvantages in the angiogenesis process compared to individualIFN treatment.We treated EA.hy926 cells with 10000 U/I IFN (IFN-group), 12,5uME (E-group), the combination of both drugs (IFN-E-group) or vehicles(C-group). We performed the MTT assay to determine cell viabilityat 72 h, constructing the dose-response curves to calculate theIC50 values. Combination index was also calculated (Compusyn).Besides, we performed the wound healing assay to determine migrationat 6 h and invasion assays in transwell chambers at 24 h. Theresults were tested by one-way ANOVA, followed by Tukey?s test (3independent experiments; n=4 in each one). As expected, IFN-Egroupshowed a higher decrease in cell viability (-63%*#) comparedto monodrug therapy: IFN-group (-22%*), E-group (-21%*). Combinationindex showed synergism between IFN and E. In the migrationassay, IFN-E-group did not show a significant decrease (-16 %*)compared to monodrug therapy: IFN-group (-16%*) and E-group(-14%*). Finally, IFN-E-group showed a significant diminution inthe invasion assay(-96 %* #) compared to monodrug therapy: IFNgroup(-33%*) and E-group (-87%*). * p